Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Chemomab Therapeutics Ltd. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +3 vs. Q2 2021
- Shares held
- 3.24M
- +155.8K (+5.0%) vs. Q2 2021
- Total value
- $35.9M
- −$22.8M (−38.8%) vs. Q2 2021
- New holders
- 7
- 1 more added
- Sold out
- 4
- 4 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 2,578,174 | $28.6M | 0.32% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 285,264 | $3.16M | 0.72% | −5,270−1.8% | Reduced |
| ARK Investment Management LLCSuperinvestorARK Invest | 180,523 | $2.00M | 0.00% | +180,523 | New |
| Advisor Group Holdings, Inc. | 54,821 | $608.0K | 0.00% | +54,821 | New |
| Boothbay Fund Management, LLC | 43,459 | $482.0K | 0.02% | −11,270−20.6% | Reduced |
| Meitav Dash Investments Ltd | 37,567 | $416.0K | 0.01% | −3,097−7.6% | Reduced |
| State Street Corp | 30,504 | $338.0K | 0.00% | +30,504 | New |
| Geode Capital Management, LLC | 13,738 | $152.0K | 0.00% | +13,738 | New |
| Apollon Wealth Management, LLC | 12,000 | $133.0K | 0.02% | +12,000 | New |
| Yahav Achim Ve Achayot - Provident Funds Management Co Ltd. | 3,097 | $34.0K | 0.03% | +3,097 | New |
| UBS Group AG | 1,751 | $19.0K | 0.00% | +1,612+1,159.7% | Added |
| Spire Wealth Management | 500 | $6.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 95 | $1.00K | 0.00% | −68−41.7% | Reduced |
| Tower Research Capital LLC (TRC) | 49 | $1.00K | 0.00% | +49 | New |
| Ironwood Financial, llc | 7 | $0 | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −63,554−100.0% | Sold out |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −44,035−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −13,180−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −51−100.0% | Sold out |